{
  "subset": "indication",
  "disease": "Neurotransmitter disorders",
  "relation": "indication",
  "gold_drugs": [
    "desloratadine",
    "escitalopram",
    "kuvantm therapy"
  ],
  "seeds_initial": [
    "Levodopa",
    "Carbidopa",
    "Baclofen",
    "Rasagiline",
    "Tetrabenazine",
    "Donepezil",
    "Selegiline",
    "Amantadine",
    "Neratinib",
    "Entacapone",
    "Fluoxetine",
    "Methylphenidate"
  ],
  "seed_history": [
    [
      "Levodopa",
      "Carbidopa",
      "Baclofen",
      "Rasagiline",
      "Tetrabenazine",
      "Donepezil",
      "Selegiline",
      "Amantadine",
      "Neratinib",
      "Entacapone",
      "Fluoxetine",
      "Methylphenidate"
    ],
    [
      "Levodopa",
      "Rasagiline",
      "Selegiline",
      "Amantadine",
      "Tetrabenazine",
      "Methylphenidate",
      "Dextroamphetamine",
      "Clonidine",
      "Buspirone",
      "Aripiprazole",
      "Desvenlafaxine",
      "Atomoxetine"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_levodopa",
          "name": "Levodopa"
        },
        "score": 0.55,
        "graph_snapshot_ref": "GE_H1_round5",
        "key_assumptions": [
          "依据神经递质疾病的临床适用性",
          "不良效应可能影响药物的净效益"
        ],
        "caveats": [
          "缺乏明确的机制链条，需补足支持"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_rasagiline",
          "name": "Rasagiline"
        },
        "score": 0.5,
        "graph_snapshot_ref": "GE_H2_round5",
        "key_assumptions": [
          "对帕金森病有实证支持",
          "不良反应需进一步评估"
        ],
        "caveats": [
          "缺乏强有力的机制链接"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_selegiline",
          "name": "Selegiline"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H3_round5",
        "key_assumptions": [
          "针对抑郁及帕金森的临床应用",
          "副作用需进一步确认"
        ],
        "caveats": [
          "机制反馈不足"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_amantadine",
          "name": "Amantadine"
        },
        "score": 0.4,
        "graph_snapshot_ref": "GE_H4_round5",
        "key_assumptions": [
          "可改善帕金森症状",
          "副作用需适度管理"
        ],
        "caveats": [
          "更多机制支持数据缺乏"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H5",
        "candidate": {
          "id": "drug_tetrabenazine",
          "name": "Tetrabenazine"
        },
        "score": 0.4,
        "graph_snapshot_ref": "GE_H5_round5",
        "key_assumptions": [
          "有助于运动障碍的治疗",
          "副作用可能影响应用"
        ],
        "caveats": [
          "缺乏针对症状的有效支持"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H6",
        "candidate": {
          "id": "drug_methylphenidate",
          "name": "Methylphenidate"
        },
        "score": 0.38,
        "graph_snapshot_ref": "GE_H6_round5",
        "key_assumptions": [
          "适应于多动症",
          "副作用可能影响其应用"
        ],
        "caveats": [
          "缺乏机制支持的明确数据"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H7",
        "candidate": {
          "id": "drug_dextroamphetamine",
          "name": "Dextroamphetamine"
        },
        "score": 0.35,
        "graph_snapshot_ref": "GE_H7_round5",
        "key_assumptions": [
          "可用于注意缺陷多动障碍",
          "副作用需妥善考虑"
        ],
        "caveats": [
          "迫切需要机制的进一步验证"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H8",
        "candidate": {
          "id": "drug_clonidine",
          "name": "Clonidine"
        },
        "score": 0.3,
        "graph_snapshot_ref": "GE_H8_round5",
        "key_assumptions": [
          "用于治疗焦虑及抗抑郁",
          "副作用影响需进一步探讨"
        ],
        "caveats": [
          "机制支持材料不足"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H9",
        "candidate": {
          "id": "drug_buspirone",
          "name": "Buspirone"
        },
        "score": 0.29,
        "graph_snapshot_ref": "GE_H9_round5",
        "key_assumptions": [
          "可用于焦虑症",
          "副作用问题需处理"
        ],
        "caveats": [
          "机制支持不明确"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H10",
        "candidate": {
          "id": "drug_aripiprazole",
          "name": "Aripiprazole"
        },
        "score": 0.26,
        "graph_snapshot_ref": "GE_H10_round5",
        "key_assumptions": [
          "用于精神分裂症",
          "副作用需更明确"
        ],
        "caveats": [
          "机制提高确认紧迫性"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H11",
        "candidate": {
          "id": "drug_desvenlafaxine",
          "name": "Desvenlafaxine"
        },
        "score": 0.2,
        "graph_snapshot_ref": "GE_H11_round5",
        "key_assumptions": [
          "抗抑郁效果需支持",
          "副作用问题未得到应对"
        ],
        "caveats": [
          "机制连接不充分"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H12",
        "candidate": {
          "id": "drug_atomoxetine",
          "name": "Atomoxetine"
        },
        "score": 0.18,
        "graph_snapshot_ref": "GE_H12_round5",
        "key_assumptions": [
          "有助于多动症治疗",
          "副作用因素需克服"
        ],
        "caveats": [
          "缺乏有效的机制链接"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Disease",
          "reason": "大部分药物已明确针对神经递质疾病的适应性。"
        }
      ],
      "remaining_gaps": [
        "机制链条不够明确，需更多支持数据。"
      ]
    },
    "seed_retrospective": {
      "batches": [],
      "lessons": []
    },
    "prompt_patches": [],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that could be indicated for the rare disease 'Neurotransmitter disorders'. Return only names.\n\n# Heuristics:\n- When Evaluating combinations of dopaminergic drugs: then Consider potential for adverse effects such as nausea and dysregulation.\n- When Investigating treatment options for neurotransmitter disorders: then Focus on long-term safety profiles and patient-reported outcomes."
}